Home Ingredients 5-Loxin® (Boswellia AKBA — PLT/OmniActive)
Joint HealthAnti-Inflammatory

5-Loxin® (Boswellia AKBA — PLT/OmniActive)

Boswellia serrata
Evidence Level
Strong
3 Clinical Trials
3 Documented Benefits
4/5 Evidence Score

5-Loxin® is a branded Boswellia serrata gum resin extract standardized to a high level (at least 30%) of AKBA (3-O-acetyl-11-keto-beta-boswellic acid), the single most potent anti-inflammatory boswellic acid. AKBA blocks 5-lipoxygenase (5-LOX), an enzyme that drives the production of inflammatory leukotrienes in joints. Standardizing to AKBA is what separates 5-Loxin from ordinary boswellia, and it has been tested in several randomized controlled trials for knee osteoarthritis.

Studied Dose 100 to 250 mg once daily. Knee osteoarthritis trials used 100 mg/day and 250 mg/day over 90 days, with benefits seen as early as 7 days at the higher dose.
Active Compound Boswellia serrata gum resin extract standardized to at least 30% AKBA (3-O-acetyl-11-keto-beta-boswellic acid), the most potent 5-LOX-inhibiting boswellic acid.

Benefits

Knee osteoarthritis and joint comfort

In double-blind, placebo-controlled trials, 5-Loxin significantly reduced pain and improved physical function scores in people with knee osteoarthritis, with the 250 mg dose showing improvement within a week.

Supported by Trial 3, Trial 1

Joint mobility and stiffness

By calming the inflammatory cascade in the joint, the extract supports easier movement and reduced morning stiffness, complementing the pain benefits measured in clinical studies.

Supported by Trial 3

Cartilage-protective signaling

Trials reported reductions in matrix metalloproteinase-3 (MMP-3), an enzyme that breaks down cartilage, suggesting the extract supports the joint structure and not only symptoms.

Supported by Trial 1, Trial 3

Mechanism of action

1

5-LOX inhibition

AKBA selectively inhibits 5-lipoxygenase, lowering the production of pro-inflammatory leukotrienes that drive swelling and pain in arthritic joints.

2

Reduced cartilage-degrading enzymes

The extract lowers MMP-3 activity, an enzyme linked to the breakdown of joint cartilage, helping protect the joint matrix over time.

Clinical trials

1
5-Loxin for Knee Osteoarthritis — RCT
PubMed

Double-blind, randomized, placebo-controlled trial of 5-Loxin (100 mg and 250 mg/day) in patients with knee osteoarthritis over 90 days. (Sengupta et al. 2008, Arthritis Research & Therapy)

Adults with knee osteoarthritis.

Both doses significantly improved pain and function versus placebo, with the 250 mg dose producing benefits as early as 7 days and reducing the cartilage-degrading enzyme MMP-3.

2
5-Loxin vs Aflapin for Osteoarthritis — RCT
PubMed

Comparative randomized controlled study of 5-Loxin and Aflapin (a related boswellia extract) against placebo in knee osteoarthritis. (Sengupta et al. 2010, International Journal of Medical Sciences)

Adults with knee osteoarthritis.

Both boswellia extracts significantly improved pain and physical-function scores versus placebo over 90 days, confirming the AKBA-standardized approach.

3
Boswellia AKBA Extract for Knee OA — RCT
PubMed

Double-blind, randomized, placebo-controlled clinical study evaluating an AKBA-enriched boswellia extract in knee osteoarthritis. (Vishal et al. 2011, International Journal of Medical Sciences)

Adults with knee osteoarthritis.

The extract significantly reduced pain and stiffness and improved joint function versus placebo, supporting the consistency of the osteoarthritis findings.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated — adverse events in trials were comparable to placebo.
Mild digestive upset, such as nausea or acid reflux, is occasionally reported.
Rarely, skin rash or headache has been noted.

Important Drug interactions

Anti-inflammatory drugs (NSAIDs) — additive anti-inflammatory effect; may allow dose adjustment under guidance.
Immunosuppressants — boswellia modulates immune signaling; use cautiously.
Anticoagulants — theoretical additive effect; monitor if combined.

More Joint Health Ingredients

Joint Health
Curcuwin Ultra+® (144× Bioavailable Curcumin — OmniActive)
Curcuwin Ultra+® is OmniActive's highly bioavailable curcumin — distinguished by 144× grea…
Joint Health
NEM® (Natural Eggshell Membrane — ESM Technologies)
NEM® is the branded standardized natural eggshell membrane developed by ESM Technologies (…
Joint Health
Undenatured Type II Collagen
Undenatured Type II Collagen (sometimes abbreviated UC-2 or native Type II collagen) is a…
Joint Health
Dynagenix® (Water-Soluble Boswellia for Joint + Muscle Recovery — PLT Health)
Dynagenix® is PLT Health Solutions' next-generation water-soluble, neutral-tasting Boswell…

Related articles from our blog

📝 Article
The 7 Best Joint Supplements of 2026
Joint supplements are a multi-billion-dollar category built on hope and habit. Walk the aisle and you will see the same…

Frequently asked questions about 5-Loxin® (Boswellia AKBA — PLT/OmniActive)

What is 5-Loxin?

5-Loxin® is a branded Boswellia serrata gum resin extract standardized to a high level (at least 30%) of AKBA (3-O-acetyl-11-keto-beta-boswellic acid), the single most potent anti-inflammatory boswellic acid.

What is 5-Loxin used for?

5-Loxin is researched primarily for Joint Health and Anti-Inflammatory. In double-blind, placebo-controlled trials, 5-Loxin significantly reduced pain and improved physical function scores in people with knee osteoarthritis, with the 250 mg dose showing improvement within a week.

What is the recommended dosage of 5-Loxin?

The clinically studied dose is 100 to 250 mg once daily. Knee osteoarthritis trials used 100 mg/day and 250 mg/day over 90 days, with benefits seen as early as 7 days at the higher dose. Always follow the product label and check with a healthcare provider for personal advice.

Is 5-Loxin safe, and does it have side effects?

For most healthy adults, 5-Loxin is well tolerated at studied doses. Reported effects can include: Generally well-tolerated — adverse events in trials were comparable to placebo. Mild digestive upset, such as nausea or acid reflux, is occasionally reported. It may also interact with some medications. 5-Loxin is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does 5-Loxin interact with any medications?

Possible interactions include: Anti-inflammatory drugs (NSAIDs) — additive anti-inflammatory effect; may allow dose adjustment under guidance. Immunosuppressants — boswellia modulates immune signaling; use cautiously. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for 5-Loxin?

NutraSmarts rates the evidence for 5-Loxin as Strong (4 out of 5). It is backed by 3 clinical trials and 3 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Sengupta K, Alluri KV, Satish AR, et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther. 2008;10(4):R85..PubMedUsed to support: Pivotal RCT showing pain and function benefit in knee osteoarthritis.
  2. Sengupta K, Krishnaraju AV, Vishal AA, et al. Comparative efficacy and tolerability of 5-Loxin and Aflapin against osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study. Int J Med Sci. 2010;7(6):366-77..PubMedUsed to support: RCT confirming osteoarthritis benefit of AKBA-standardized boswellia.
  3. Vishal AA, Mishra A, Raychaudhuri SP. A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of aflapin in subjects with osteoarthritis of knee. Int J Med Sci. 2011;8(7):615-22..PubMedUsed to support: RCT of AKBA-enriched boswellia in knee osteoarthritis.